Page 8 - Nursing Matters June 2021 Vol 12

As per the South African National DTG not become ineffective easily, it References:
Department of Health updated 2019 also manages to suppress HIV rapidly, 1. AVERT. HIV and AIDS in South Africa [Internet]. 2020 [cited
2020 Dec 10];Available from: https://www.avert.org/
16
ART guidelines, viral loads should first allowing the patient’s immune system professionals/hiv-around-world/sub-saharan-africa/south-
africa
be performed at 6 months following ART time to recuperate. This was seen in the 2. Atta MG, De Seigneux S, Lucas GM. Clinical Pharmacology
initiation. Importantly, viral load is not ADVANCE clinical trial which compared in HIV Therapy. Clin J Am Soc Nephrol [Internet]
from:
https://cjasn.
2019;14(3):435–44.
Available
asnjournals.org/lookup/doi/10.2215/CJN.02240218
required at time of ART initiation, since it two DTG-based regimens to South Africa’s 3. Bardal SK, Waechter JE, Martin DS. Infectious Diseases
can be expected to be high in the absence previous standard of care, an EFV-based [Internet]. In: Applied Pharmacology. Elsevier; 2011. p. 233–
91.Available from: https://linkinghub.elsevier.com/retrieve/
pii/B978143770310800018X
7
of ARVs to suppress it. regimen. Whilst DTG and EFV were 4. Kolakowska A, Maresca AF, Collins IJ, Cailhol J. Update on
noted to both be effective in managing Adverse Effects of HIV Integrase Inhibitors. Curr Treat Options
Infect Dis [Internet] 2019;11(4):372–87. Available from:
Further management of the patient is HIV infection, patients on DTG-regimens http://link.springer.com/10.1007/s40506-019-00203-7
dependent on this initial result: achieved viral suppression sooner than 5. Zash, R; Holmes, L; Diseko, M; Jacobson, D; Mayondi G et al.
Update on neural tube defects with antiretroviral exposure in
the Tsepamo study, Botswana [Internet]. 2020. Available from:
• VL < 50 cp/mL - this implies that the those on EFV. This is particularly important http://programme.aids2020.org/Abstract/Abstract/11299
virus is suppressed, and the patient in reducing disease progression and aid 6. Venter WDF, Sokhela S, Simmons B, et al. Dolutegravir
with emtricitabine and tenofovir alafenamide or tenofovir
can continue with their ARV treatment in preventing HIV transmission. disoproxil fumarate versus efavirenz, emtricitabine, and
tenofovir disoproxil fumarate for initial treatment of HIV-1
as prescribed, with a repeat VL infection (ADVANCE): week 96 results from a randomised,
phase 3, n. Lancet HIV [Internet] 2020;7(10):e666–76.
only required annually thereafter if Guidelines on managing virological Available from: https://linkinghub.elsevier.com/retrieve/pii/
S2352301820302411
continuously suppressed. failure continue to evolve as we learn 7. Venter WDF, Moorhouse M, Sokhela S, et al. Dolutegravir
plus Two Different Prodrugs of Tenofovir to Treat HIV. N Engl J
• VL ≥ 50 cp/mL - this is considered more about ARVs and the likelihood of Med [Internet] 2019;381(9):803–15. Available from: http://
www.nejm.org/doi/10.1056/NEJMoa1902824
a medical emergency and must developing resistance mutations. Because 8. Walmsley SL, Antela A, Clumeck N, et al. Dolutegravir plus
Abacavir–Lamivudine for the Treatment of HIV-1 Infection.
therefore be evaluated as soon as of its high genetic barrier, resistance to N Engl J Med [Internet] 2013;369(19):1807–18. Available
from: http://www.nejm.org/doi/10.1056/NEJMoa1215541
possible. This includes assessment of DTG develops very slowly, and elevated 9. Stellbrink H-J, Reynes J, Lazzarin A, et al. Dolutegravir
adherence, presence of concurrent VLs in a patient on a DTG-based regimen in antiretroviral-naive adults with HIV-1. AIDS [Internet]
2013;27(11):1771–8. Available from: http://journals.lww.
com/00002030-201307170-00010
infections, ensuring correct ART is likely to be related to poor adherence. 10. Molina J-M, Clotet B, van Lunzen J, et al. Once-daily
dosing, monitoring for drug-drug As a result, patients should be on a DTG- dolutegravir versus darunavir plus ritonavir for treatment-naive
adults with HIV-1 infection (FLAMINGO): 96 week results
interactions, and considering based regimen for at least 2 years, with from a randomised, open-label, phase 3b study. Lancet HIV
[Internet] 2015;2(4):e127–36. Available from: https://
linkinghub.elsevier.com/retrieve/pii/S2352301815000272
the presence of ARV resistance at least 3 VL ≥ 1000 cp/mL before 11. Orrell C, Hagins DP, Belonosova E, et al. Fixed-dose
mutations. 16 Once adherence considering a switch to second-line ART. combination dolutegravir, abacavir, and lamivudine versus
16
ritonavir-boosted atazanavir plus tenofovir disoproxil fumarate
counselling has been done, a repeat This is in comparison to EFV-based first-line and emtricitabine in previously untreated women with HIV-
1 infection (ARIA): week 48 results from a randomised,
VL done 3 months thereafter is ART, which requires only 2 consecutive open-label. Lancet HIV [Internet] 2017;4(12):e536–46.
Available from: https://linkinghub.elsevier.com/retrieve/pii/
S2352301817300954
indicated and the patient managed VL ≥ 1000 cp/mL before considering a 12. Aboud M, Kaplan R, Lombaard J, et al. Dolutegravir versus
accordingly. regimen switch because of EFV’s lower ritonavir-boosted lopinavir both with dual nucleoside reverse
transcriptase inhibitor therapy in adults with HIV-1 infection
barrier to resistance mutations. in whom first-line therapy has failed (DAWNING): an open-
label, non-inferiority, phase 3b trial. Lancet Infect Dis [Internet]
DTG and the VL 2019;19(3):253–64. Available from: https://linkinghub.
elsevier.com/retrieve/pii/S1473309919300362
Conclusion 13. Trottier B, Lake JE, Logue K, et al. Dolutegravir/abacavir/
lamivudine versus current ART in virally suppressed patients
HIV, if uncontrolled, is able to mutate or (STRIIVING): a 48-week, randomized, non-inferiority, open-
label, Phase IIIb study. Antivir Ther [Internet] 2017;22(4):295–
adapt itself each time a new viral copy Dolutegravir, despite recent concerns 305. Available from: https://www.intmedpress.com/journals/
avt/abstract.cfm?id=3166&pid=48
is made. If this is done in the presence of around weight gain, is an excellent 14. van Wyk J, Ajana F, Bisshop F, et al. Efficacy and Safety of
Switching to Dolutegravir/Lamivudine Fixed-Dose 2-Drug
ARVs, mutations to these drugs develop addition to the South African ART Regimen vs Continuing a Tenofovir Alafenamide–Based 3- or
4-Drug Regimen for Maintenance of Virologic Suppression
and accumulate. A genetic barrier to programme. Not only is it well tolerated, in Adults Living With Human Immunodeficiency Virus
Type 1: Phas. Clin Infect Dis [Internet] 2020;71(8):1920–
resistance, simply put, is the number of its high genetic barrier allows it to 9. Available from: https://academic.oup.com/cid/
article/71/8/1920/5697294
mutations required to develop resistance to largely evade resistance and remain 15. Cahn P, Madero JS, Arribas JR, et al. Dolutegravir plus
lamivudine versus dolutegravir plus tenofovir disoproxil
a specific ARV. A high barrier to resistance active against HIV. The importance of fumarate and emtricitabine in antiretroviral-naive adults
with HIV-1 infection (GEMINI-1 and GEMINI-2): week
allows for the accumulation of many this cannot be emphasised enough in 48 results from two multicentre, double-blind, randomised,
non-inferior. Lancet [Internet] 2019;393(10167):143–55.
mutations before a drug can no longer ensuring patients remain susceptible to Available from: https://linkinghub.elsevier.com/retrieve/pii/
S0140673618324620
be used due to resistance and subsequent first-line ART regimens, allowing for ease 16. Republic of South Africa National Department of Health. 2019
decreased efficacy. HIV drug resistance of use, and in doing so encouraging ART Clinical Guidelines for the Management of HIV in Adults,
19
Pregnancy, Adolescents, Children, Infants and Neonates
[Internet]. [cited 2020 Nov 11];Available from: https://
is able to severely impact the effectiveness treatment adherence, preservation of sahivsoc.org/Files/2019 ART Guideline 28042020 pdf.pdf
of ART regimens and programmes, future ART options, and preventing the use 17. Meyer-Ruth, G; Jamieson, L; Masuku, S; Venter, F; Johnson
L. The impact of dolutegravir in first-line adult ART on HIV
allowing for increased mortality, limited of more costly second- and third-line ARVs. transmission and cost of HIV in South Africa [Internet].
2018. Available from: https://www.sahivsoc2018.co.za/
options for future regimens and increased Concurrently, the timeous use of viral load wp-content/uploads/2018/11/9C_Gesine-Meyer-Rath-DTG-
CEA-October-2018-.pdf
cost implications. testing to monitor therapeutic response 18. AVERT. What is an undetectable viral load? [Internet]. Living
with HIV. 2020 [cited 2020 Dec 10];Available from: https://
remains vital in identifying patients with www.avert.org/living-with-hiv/antiretroviral-treatment/what-
does-undetectable-mean
DTG is one such drug with a high adherence issues and addressing these 19. Gega A, Kozal MJ. New technology to detect low-level drug-
resistant HIV variants. Future Virol [Internet] 2011;6(1):17–
barrier to resistance. Not only does concerns early on. 26. Available from: https://www.futuremedicine.com/
doi/10.2217/fvl.10.77
HIV Nursing Matters | June 2021 | page 6